BGT226

SKU: orb1301099

Description

BGT226 (NVP-BGT226) is a potent dual inhibitor of PI3K and mTOR, demonstrating high potency against PI3Kα, β, and γ isoforms. It is utilized in preclinical research to investigate oncogenic signaling pathways and has been studied in various cancer cell lines and in vivo tumor models.

Research Area

Cell Biology, Signal Transduction

Key Properties

• CAS Number: 915020-55-2
• MW: 534.53
• Purity: 99.78% (May vary between batches)
• Formula: C₂₈H₂₅F₃N₆O₂
• SMILES: COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1
• Target: PI3K,Autophagy,mTOR
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (1.87 mM);DMSO:65 mg/mL (121.6 mM)

Bioactivity

• Target IC50:
  PI3Kα:4 nM|PI3Kβ:63 nM|PI3Kγ:38 nM
• In Vivo:
  BGT226 significantly delayed tumor growth on the transplanted tumor animal model. This effect was dose-dependent, accompanied by inhibition of p-p70 S6 kinase cytoplasmic expression and autophagy body formation.
• In Vitro:
  Growth inhibition experiment showed that BGT226 had antitumor activity. BGT226 significantly inhibited cell growth with IC50 < 20 nM. BGT226 also induced cancer cell apoptosis at nanomolar concentration, IC50 ≤ 25 nM.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

PI3K, PI3Kγ, PI3Kβ, PI3Kα, Autophagy, BGT 226, BGT226, BGT-226, BGT226 free base, mTOR, NVP-BGT 226, NVP-BGT226, NVP-BGT-226, Mammalian target of Rapamycin

Compound Identifiers

PubChem CID

11978790